RxDoctor Payments Data

Sue Eckhardt

Medical Oncology · Austin, TXNPI 1043300726

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,399,674 of the $1,451,666 with a category attached, or 96.4%. Exelixis Inc. accounts for 97.6% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $1,034,532, more than ten times the $9,972 reported in 2019. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,451,666in general payments, 2019–2025

Across 77 payments — averaging $18,853 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$1.4M
  • Amgen$25K
  • Merck$10K
$21,401in research payments, 2019–2025

Across 2 payments — averaging $10,701 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$18K
  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Consulting fees$29,3602%
  • Speaking & faculty fees$1,399,67496%
  • Travel & lodging$18,0021%
  • Food & beverage$4,6290%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exelixis Inc.45$1,416,582
Amgen20$25,111
Merck12$9,972

How this compares

$1,451,666 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.

See all medical oncology providers in Texas →

Other medical oncology in Austin

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →